Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12011135 | 0.90 | PTGER4 (0.65) | PTGER4 | |
| SCHEMBL3561381 | 0.89 | PTGER4 (0.79) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL2295490 | 0.88 | PTGER4 (1.00) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL9606833 | 0.85 | PTGER4 (0.58) | PTGER4 | |
| SCHEMBL2295041 | 0.84 | PTGER4 (1.00) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL4683232 | 0.84 | PTGER4 (0.68) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL2296948 | 0.83 | PTGER4 (0.61) | PTGER4 | |
| SCHEMBL2300769 | 0.83 | PTGER4 (1.00) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL2298465 | 0.83 | PTGER4 (0.68) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL2429985 | 0.83 | PTGER4 (0.88) | PTGER4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252833-B2 | Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-08-28 | — | — | US | claimed |
| EP-2457897-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-05-30 | — | — | EP | claimed |
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | claimed |
| US-8252833-B2 | Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-08-28 | — | — | US | disclosed |
| US-8252833-B2 | Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-08-28 | — | — | US | disclosed |
| US-8252833-B2 | Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-08-28 | — | — | US | disclosed |
| EP-2457897-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-05-30 | — | — | EP | disclosed |
| EP-2457897-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| EP-1979316-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007088190-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088190-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885CYP1A2 284/4885CYP2D6 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.